![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 Muscle Loss Explained |](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=1050961973852737)
glp-1 receptor agonists should be avoided in patients with
Shipping Estimate
glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 Muscle Loss Explained |
EUR27.24
EUR49.24
Pay in 4 interest-free payments of $6.81 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 Muscle Loss Explained |](https://lifesciencedaily.news/wp-content/uploads/2026/06/GLP1_LifeSciences_1200x750_under1MB.jpg)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 Muscle Loss Explained |](https://www.nejm.org/cms/asset/5780f2cd-5e61-47ad-b5f8-a8570d65c1ed/nejmra2500106_f1.jpg)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 Muscle Loss Explained |](https://b1167102.smushcdn.com/1167102/wp-content/uploads/2025/07/GLP01.jpg?lossy=2&strip=1&webp=1)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 Muscle Loss Explained |](https://i.ytimg.com/vi/-MSmaL7eFHY/hq720.jpg?sqp=-oaymwE7CK4FEIIDSFryq4qpAy0IARUAAAAAGAElAADIQj0AgKJD8AEB-AH-CYAC0AWKAgwIABABGBEgaChyMA8=&rs=AOn4CLAd0vv650xm5dH5-VZ1xOhjCDzz2g)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 Muscle Loss Explained |](https://www.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/721135/fendo-12-721135-HTML/image_m/fendo-12-721135-g001.jpg)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of GLP-1 Muscle Loss Explained |](https://assets.cureus.com/uploads/figure/file/1358875/article_river_6ec20b70dc8011efab01038c9fa496dc-figure1128.png)
00188-2/asset/060af149-96d8-44a2-9e4d-318ecc8ae69e/main.assets/gr1_lrg.jpg)
